TY - JOUR
T1 - ACR Appropriateness Criteria® on Metastatic Bone Disease
AU - Roberts, Catherine C.
AU - Daffner, Richard H.
AU - Weissman, Barbara N.
AU - Bancroft, Laura
AU - Bennett, D. Lee
AU - Blebea, Judy S.
AU - Bruno, Michael A.
AU - Fries, Ian Blair
AU - Germano, Isabelle M.
AU - Holly, Langston
AU - Jacobson, Jon A.
AU - Luchs, Jonathan S.
AU - Morrison, William B.
AU - Olson, Jeffrey J.
AU - Payne, William K.
AU - Resnik, Charles S.
AU - Schweitzer, Mark E.
AU - Seeger, Leanne L.
AU - Taljanovic, Mihra
AU - Wise, James N.
AU - Lutz, Stephen T.
PY - 2010/6
Y1 - 2010/6
N2 - Appropriate imaging modalities for screening, staging, and surveillance of patients with suspected and documented metastatic disease to bone include 99mTc bone scanning, MRI, CT, radiography, and 2-[18F]fluoro-2-deoxyglucose-PET. Clinical scenarios reviewed include asymptomatic stage 1 breast carcinoma, symptomatic stage 2 breast carcinoma, abnormal bone scan results with breast carcinoma, pathologic fracture with known metastatic breast carcinoma, asymptomatic well-differentiated and poorly differentiated prostate carcinoma, vertebral fracture with history of malignancy, non-small-cell lung carcinoma staging, symptomatic multiple myeloma, osteosarcoma staging and surveillance, and suspected bone metastasis in a pregnant patient. No single imaging modality is consistently best for the assessment of metastatic bone disease across all tumor types and clinical situations. In some cases, no imaging is indicated. The recommendations contained herein are the result of evidence-based consensus by the ACR Appropriateness Criteria® Expert Panel on Musculoskeletal Radiology.
AB - Appropriate imaging modalities for screening, staging, and surveillance of patients with suspected and documented metastatic disease to bone include 99mTc bone scanning, MRI, CT, radiography, and 2-[18F]fluoro-2-deoxyglucose-PET. Clinical scenarios reviewed include asymptomatic stage 1 breast carcinoma, symptomatic stage 2 breast carcinoma, abnormal bone scan results with breast carcinoma, pathologic fracture with known metastatic breast carcinoma, asymptomatic well-differentiated and poorly differentiated prostate carcinoma, vertebral fracture with history of malignancy, non-small-cell lung carcinoma staging, symptomatic multiple myeloma, osteosarcoma staging and surveillance, and suspected bone metastasis in a pregnant patient. No single imaging modality is consistently best for the assessment of metastatic bone disease across all tumor types and clinical situations. In some cases, no imaging is indicated. The recommendations contained herein are the result of evidence-based consensus by the ACR Appropriateness Criteria® Expert Panel on Musculoskeletal Radiology.
UR - http://www.scopus.com/inward/record.url?scp=84928096179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928096179&partnerID=8YFLogxK
U2 - 10.1016/j.jacr.2010.02.015
DO - 10.1016/j.jacr.2010.02.015
M3 - Review article
C2 - 20522392
AN - SCOPUS:84928096179
SN - 1546-1440
VL - 7
SP - 400
EP - 409
JO - Journal of the American College of Radiology
JF - Journal of the American College of Radiology
IS - 6
ER -